| Drug Name: | Ifosfamide (3778-73-2) |
|---|---|
| PubChem ID: | 3690 |
| SMILES: | C1CN(P(=O)(OC1)NCCCl)CCCl |
| InchiKey: | HOMGKSMUEGBAAB-UHFFFAOYSA-N |
| Therapeutic Category: | Alkylating Agents, Antineoplastic Agents, Noxae |
| Molecular Weight (dalton) | : | 261.089 |
| LogP | : | 1.884 |
| Ring Count | : | 0 |
| Hydrogen Bond Acceptor Count | : | 2 |
| Hydrogen Bond Donor Count | : | 1 |
| Total Polar Surface Area | : | 41.57 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Cisplatin (15663-27-1) | Renal Toxicity | Synergistic | cisplatin damages the kidney tubules so that the clearance of the ifosfamide metabolites is reduced and their toxic effects are thereby increased. | Ifosfamide nephrotoxicity: deleterious effect of previous cisplatin administration |
| Paclitaxel (33069-62-4) | Cell-Mediated Cytotoxicity | Synergistic | unknown | cIfosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clin |
| Rifampicin (13292-46-1) | Decreased Efficacy | Antagonistic | Rifampicin is an inducer of the cytochrome P450 isoenzymes CYP3A4 and CYP2B6, which are involved in the metabolism of ifosfamide | Modulation of the cytochrome P450–mediated metabolism of ifosfamide by ketoconazole and rifampin |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Aminoaciduria | Beta-2-microglobulin (P61769) | Proximal tubular toxicity was indicated by increased urine beta 2 microglobulin excretion@ which leads to generalised aminoaciduria. [ ADR Type 1 ] | Nephrotoxicity after ifosfamide |
| Anxiety | Alpha-2A adrenergic receptor (P08913) | Alpha(2A)-AR knock-out mice appear more anxious than wild-type C57 Bl/6 mice in the rearing and light-dark models of anxiety after injection stress [ ADR Type 3 ] | Alpha-adrenergic receptors mediate imipramine/alarm substance-induced reaction in rats |
| Glycosuria | Beta-2-microglobulin (P61769) | Proximal tubular toxicity was indicated by increased urine beta 2 microglobulin excretion@ which leads to glycosuria [ ADR Type 1 ] | Nephrotoxicity after ifosfamide |
| Hypophosphataemia | Beta-2-microglobulin (P61769) | Proximal tubular toxicity was indicated by increased urine beta 2 microglobulin excretion@ which leads to phosphaturia and hypophosphataemia. [ ADR Type 1 ] | Nephrotoxicity after ifosfamide |
| Insensitive To The Antidepressant Effects | Alpha-2A adrenergic receptor (P08913) | The genetic knock-out of the alpha(2A)-AR makes mice LESS ACTIVE in a modified version of Porsolt#s forced swim test and insensitive to the antidepressant effects of the tricyclic drug imipramine in this paradigm [ ADR Type 3 ] | Alpha-adrenergic receptors mediate imipramine/alarm substance-induced reaction in rats |
| Reduce Arterial Rigidity | Elastin (P15502) | The combination of binding to elastin and reduction in uptake of calcium and phosphate into the smooth muscle could be a mechanism for reducing arterial rigidity seen in the elderly and hypertensive patient [ ADR Type 1 ] | Cardiovascular protective properties of indapamide |
| Stimulated Ornithine Decarboxylase Activity | Ornithine decarboxylase (P11926) | Single dose of imipramine stimulated ornithine decarboxylase activity 7-fold and decreased S-adenosylmethionine decarboxylase activity to 50% from the control level [ ADR Type 1 ] | The inverse changes of mouse brain ornithine and S-adenosylmethionine decarboxylase activities by chlorpromazine and imipramine Dependence of ornithine decarboxylase induction |
| Stimulated Ornithine Decarboxylase Activity | S-adenosylmethionine decarboxylase (P17707) | Single dose of imipramine stimulated ornithine decarboxylase activity 7-fold and decreased S-adenosylmethionine decarboxylase activity to 50% from the control level [ ADR Type 1 ] | The inverse changes of mouse brain ornithine and S-adenosylmethionine decarboxylase activities by chlorpromazine and imipramine Dependence of ornithine decarboxylase induction |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category